WallStSmart

Merck & Company Inc (MRK)vsVarex Imaging Corp (VREX)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 7596% more annual revenue ($66.57B vs $865.00M). MRK leads profitability with a 4.8% profit margin vs 2.6%. MRK appears more attractively valued with a PEG of 2.76. VREX earns a higher WallStSmart Score of 55/100 (C-).

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

VREX

Buy

55

out of 100

Grade: C-

Growth: 5.3Profit: 5.0Value: 4.0Quality: 7.0
Piotroski: 5/9Altman Z: 1.65
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-78.2%)

Margin of Safety

-78.2%

Fair Value

$83.04

Current Price

$148.78

$65.74 premium

UndervaluedFair: $83.04Overvalued
VREXUndervalued (+14.7%)

Margin of Safety

+14.7%

Fair Value

$15.95

Current Price

$18.45

$2.50 discount

UndervaluedFair: $15.95Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$365.34B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

VREX2 strengths · Avg: 9.0/10
EPS GrowthGrowth
453.4%10/10

Earnings expanding 453.4% YoY

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

Areas to Watch

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.8x4/10

Trading at 8.8x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

VREX4 concerns · Avg: 3.8/10
P/E RatioValuation
34.9x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
3.7%4/10

3.7% revenue growth

Altman Z-ScoreHealth
1.654/10

Distress zone — elevated risk

Market CapQuality
$779.32M3/10

Smaller company, higher risk/reward

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bull Case : VREX

The strongest argument for VREX centers on EPS Growth, Price/Book.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 120.4x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Bear Case : VREX

The primary concerns for VREX are P/E Ratio, Revenue Growth, Altman Z-Score. Thin 2.6% margins leave little buffer for downturns.

Key Dynamics to Monitor

VREX carries more volatility with a beta of 0.96 — expect wider price swings.

MRK is growing revenue faster at 5.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VREX scores higher overall (55/100 vs 36/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Varex Imaging Corp

HEALTHCARE · MEDICAL DEVICES · USA

Varex Imaging Corporation designs and manufactures X-ray imaging components. The company is headquartered in Salt Lake City, Utah.

Visit Website →

Want to dig deeper into these stocks?